Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

69 questions · 69 findings · 16 reviews · Heart

No studies found 12 · 17.4%GRADE not reported 1 · 1.4%Very low 10 · 14.5%Low 22 · 31.9%Moderate 20 · 29%High 4 · 5.8%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Intervention not reported

Recurrent pericarditis Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers) Intervention: colchicine with NSAID; Comparison: NSAID alone

The intervention probably leads to lower recurrent pericarditis Chest pain + (ECG changes +/‐… (moderate certainty).

1 finding from 1 review

Intervention not reported

Acute pericarditis Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers) Intervention: colchicine with NSAID; Comparison: NSAID alone

The intervention probably leads to lower acute pericarditis Chest pain + (ECG changes +/‐ echocardiographic… (moderate certainty).

1 finding from 1 review

Benznidazole vs placebo

Clinical improvement (N) (a) Heart failure (b) Sustained ventricular tachycardia · adults with both late‐stage, symptomatic Chagas disease and CCC

Benznidazole showed no clear difference in clinical improvement (N) (a) Heart failure (b) Sustained ventricular… compared with placebo (low certainty).

1 finding from 1 review

IVIg vs placebo or no treatment

Event‐free survival (no death, transplant, or left ventricular assist device) ‐ adults with myocarditis · adults with acute myocarditis

It is very uncertain whether intravenous immunoglobulin changes event‐free survival (risk of death, cardiac transplant, or left… compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Natriuretic peptide‐guided treatment vs usual care

Ventricular dysfunction (as defined by trialists) · patients without heart failure

Natriuretic peptide‐guided treatment leads to lower ventricular dysfunction (as defined by trialists) compared with standard care (high certainty).

1 finding from 1 review

Lidocaine vs disopyramide

Ventricular fibrillation · patients with myocardial infarction

It is very uncertain whether lidocaine changes ventricular fibrillation compared with disopyramide (very low certainty).

1 finding from 1 review

Lidocaine vs disopyramide

Adverse events (AEs; adverse drug reaction): cardiac blocks (high‐degree atrioventricular block and bundle) · patients with myocardial infarction

It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): cardiac blocks… compared with disopyramide (very low certainty).

1 finding from 1 review

Lidocaine vs mexiletine

Ventricular fibrillation · patients with myocardial infarction

It is very uncertain whether lidocaine changes ventricular fibrillation compared with mexiletine (very low certainty).

1 finding from 1 review

Lidocaine vs mexiletine

Adverse events (AEs; adverse drug reaction): atrioventricular block · patients with myocardial infarction

It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): atrioventricular block compared with mexiletine (very low certainty).

1 finding from 1 review

Lidocaine vs propafenone

Ventricular fibrillation · patients with myocardial infarction

It is very uncertain whether lidocaine changes ventricular fibrillation compared with propafenone (very low certainty).

1 finding from 1 review

Lidocaine vs propafenone

Neuropsychiatric adverse event · patients with myocardial infarction

It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): neuropsychiatric… compared with propafenone (very low certainty).

1 finding from 1 review

Lidocaine vs amiodarone

Ventricular fibrillation · patients with myocardial infarction

It is very uncertain whether lidocaine changes ventricular fibrillation compared with amiodarone (very low certainty).

1 finding from 1 review